{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:04:40Z","timestamp":1792011880112,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009142","name":"Cancer Care Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ejca.2019.10.034","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T14:06:23Z","timestamp":1579874783000},"page":"76-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["Indications for hyperthermic intraperitoneal chemotherapy\u00a0with cytoreductive surgery: a systematic review"],"prefix":"10.1016","volume":"127","author":[{"given":"Rebecca C.","family":"Auer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duvaraga","family":"Sivajohanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Biagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taymaa","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2019.10.034_bib1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/annonc\/mdl345","article-title":"Epidemiology of peritoneal mesothelioma: a review","volume":"18","author":"Boffetta","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2019.10.034_bib2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ijc.28373","article-title":"Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors","volume":"134","author":"Thomassen","year":"2014","journal-title":"Int J Cancer"},{"issue":"24","key":"10.1016\/j.ejca.2019.10.034_bib3","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2019.10.034_bib4","first-page":"143","article-title":"Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future","volume":"7","author":"Dehal","year":"2016","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2019.10.034_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.ejca.2019.10.034_bib6","doi-asserted-by":"crossref","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","article-title":"The transport barrier in intraperitoneal therapy","volume":"288","author":"Flessner","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"10.1016\/j.ejca.2019.10.034_bib7","first-page":"1916","article-title":"Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans","volume":"41","author":"Speyer","year":"1981","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2019.10.034_bib8","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/1097-0142(197706)39:6<2637::AID-CNCR2820390650>3.0.CO;2-S","article-title":"Effect of hyperthermia on malignant cells in\u00a0vivo. A review and a hypothesis","volume":"39","author":"Overgaard","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.10.034_bib9","first-page":"39","article-title":"Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis","volume":"169","author":"de Bree","year":"2007","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.ejca.2019.10.034_bib10","series-title":"Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach","author":"Sch\u00fcnemann","year":"2013"},{"issue":"15 Supplement 1","key":"10.1016\/j.ejca.2019.10.034_bib11","article-title":"Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer","volume":"35","author":"Lim","year":"2017","journal-title":"J Clin Oncol Conf"},{"key":"10.1016\/j.ejca.2019.10.034_bib12","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"13","author":"Spiliotis","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2019.10.034_bib13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Van Driel","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.10.034_bib14","article-title":"Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer","author":"Koole","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"18 Supplement 1","key":"10.1016\/j.ejca.2019.10.034_bib15","article-title":"A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7","volume":"36","author":"Quenet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2019.10.034_bib16","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","article-title":"8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer","volume":"15","author":"Verwaal","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2019.10.034_bib17","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J Clin Oncol"},{"issue":"15 Supplement 1","key":"10.1016\/j.ejca.2019.10.034_bib18","article-title":"Results of a randomized phase 3 study evaluating the potential benefit of a secondlook surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP- NTC01226394)","volume":"36","author":"Goere","year":"2018","journal-title":"J Clin Oncol Conf"},{"issue":"10","key":"10.1016\/j.ejca.2019.10.034_bib19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.ejca.2019.10.034_bib20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3892\/etm.2014.1599","article-title":"Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer","volume":"7","author":"Cui","year":"2014","journal-title":"Exp Ther Med"},{"issue":"3","key":"10.1016\/j.ejca.2019.10.034_bib21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9","article-title":"Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma","volume":"85","author":"Fujimoto","year":"1999","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2019.10.034_bib22","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/1097-0142(19940415)73:8<2048::AID-CNCR2820730806>3.0.CO;2-Q","article-title":"Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer: final results of a randomized controlled study","volume":"73","author":"Hamazoe","year":"1994","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2019.10.034_bib23","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"42","key":"10.1016\/j.ejca.2019.10.034_bib24","first-page":"1776","article-title":"Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study","volume":"48","author":"Yonemura","year":"2001","journal-title":"Hepato-Gastroenterology"},{"issue":"7","key":"10.1016\/j.ejca.2019.10.034_bib25","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1245\/s10434-018-6499-1","article-title":"Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival","volume":"25","author":"Verma","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"36","key":"10.1016\/j.ejca.2019.10.034_bib26","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2019.10.034_bib27","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1245\/s10434-009-0341-8","article-title":"Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution","volume":"16","author":"Chua","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2019.10.034_bib28","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2019.10.034_bib29","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00384-014-1933-8","article-title":"Comparison of serial debulking and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei of appendiceal origin","volume":"29","author":"Jarvinen","year":"2014","journal-title":"Int J Colorectal Dis"},{"issue":"2","key":"10.1016\/j.ejca.2019.10.034_bib30","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.sla.0000133183.15705.71","article-title":"Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy","volume":"240","author":"Glehen","year":"2004","journal-title":"Ann Surg"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2019.10.034_bib31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s13193-018-00870-w","article-title":"Analysis of clinical outcomes of pseudomyxoma peritonei from appendicular origin following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy-A retrospective study from INDEPSO","volume":"10","author":"Sinukumar","year":"2019","journal-title":"Ind J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2019.10.034_bib32","first-page":"CD005340","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","author":"Jaaback","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ejca.2019.10.034_bib33","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/IGC.0000000000000864","article-title":"Brief Report about the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer from Spiliotis et\u00a0al","volume":"27","author":"Harter","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2019.10.034_bib34","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/IGC.0000000000001244","article-title":"Examining survival outcomes of 852 women with advanced ovarian cancer: a multi-institutional cohort study","volume":"28","author":"May","year":"2018","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2019.10.034_bib35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1245\/s10434-009-0669-0","article-title":"Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in\u00a0vivo","volume":"17","author":"Cohen","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2019.10.034_bib36","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1002\/bjs.10788","article-title":"Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases","volume":"105","author":"Ubink","year":"2018","journal-title":"Br J Surg"},{"issue":"9","key":"10.1016\/j.ejca.2019.10.034_bib37","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamaoncol.2016.2314","article-title":"Clinical outcome from oxaliplatin treatment in stage II\/III colon cancer according to intrinsic subtypes: secondary analysis of NSABP C-07\/NRG Oncology randomized clinical trial","volume":"2","author":"Song","year":"2016","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2019.10.034_bib38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jso.23546","article-title":"The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study","volume":"109","author":"Hompes","year":"2014","journal-title":"J Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2019.10.034_bib39","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/jso.23728","article-title":"The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery","volume":"110","author":"Prada-Villaverde","year":"2014","journal-title":"J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2019.10.034_bib40","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1245\/s10434-013-3061-z","article-title":"Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States","volume":"21","author":"Turaga","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"30","key":"10.1016\/j.ejca.2019.10.034_bib41","doi-asserted-by":"crossref","first-page":"6906","DOI":"10.3748\/wjg.v22.i30.6906","article-title":"Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies","volume":"22","author":"Li","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.ejca.2019.10.034_bib42","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ijc.24290","article-title":"Recent patterns in gastric cancer: a global overview","volume":"125","author":"Bertuccio","year":"2009","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2019.10.034_bib43","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/1097-0142(20001101)89:9<1883::AID-CNCR3>3.0.CO;2-H","article-title":"Asian patients with gastric carcinoma in the United States exhibit unique clinical features and superior overall and cancer specific survival rates","volume":"89","author":"Theuer","year":"2000","journal-title":"Cancer"},{"issue":"30","key":"10.1016\/j.ejca.2019.10.034_bib44","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study","volume":"29","author":"Ohtsu","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2019.10.034_bib45","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1245\/s10434-013-3327-5","article-title":"Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis","volume":"21","author":"Magge","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2019.10.034_bib46","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1245\/s10434-015-5081-3","article-title":"Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility?","volume":"23","author":"Chia","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2019.10.034_bib47","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/00000478-199512000-00006","article-title":"Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to \u201cpseudomyxoma peritonei\u201d","volume":"19","author":"Ronnett","year":"1995","journal-title":"Am J Surg Pathol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919308196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919308196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:26:41Z","timestamp":1760732801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919308196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":47,"alternative-id":["S0959804919308196"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.10.034","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indications for hyperthermic intraperitoneal chemotherapy\u00a0with cytoreductive surgery: a systematic review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.10.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}